By Donna Loyle, communications specialist, LIMR
Researchers are testing a combination of chemotherapy with or without the immunotherapy drug Tecentriq® (atezolizumab) in treating patients with stage 3 colon cancer and deficient DNA mismatch repair.
There are two study arms to this trial. Participants in both are administered chemotherapy. Those in Arm 1 also receive atezolizumab.
Eligible patients must not have been treated previously with chemotherapy, immunotherapy, biologic or targeted therapy, or radiation therapy for colon cancer (except for one cycle of mFOLFOX6). Other inclusion and exclusion criteria apply.
This study, #A021502, is available at all Main Line Health acute care hospitals. The principal investigators and Albert DeNittis, MD, and Paul Gilman, MD. For more, visit https://www.mainlinehealth.org/research/clinical-trials/a021502